Acupuncture, Moxibustion and Meridian Research Centre, Korea Institute of Oriental Medicine, Daejeon, South Korea.
Trials. 2010 Nov 16;11:107. doi: 10.1186/1745-6215-11-107.
Previous studies of acupuncture show favourable results for both subjective and objective outcomes of dry eye. However, firm conclusions could not be drawn from these studies because the quality of the trials was too low to establish concrete evidence. Therefore, this study was designed both to avoid the flaws of the existing trials and to assess the effectiveness, cost-effectiveness and qualitative characteristics of acupuncture treatment for dry eye.
METHODS/DESIGN: One hundred fifty participants with dry eye will be recruited into three independent hospitals from different areas: Korea Institute of Oriental Medicine, DongGuk University Ilsan Oriental Hospital and Dongshin University Gwangju Oriental Hospital. The number of participants required was calculated from the data of a previous, relevant study. These patients will be randomly allocated into acupuncture treatment or artificial tear groups. Either 17 acupuncture points (bilateral BL2, GB14, TE 23, Ex1, ST1, GB20, LI4, LI11 and single GV23) will be used 3 times a week or disposable artificial tear drops (Refresh Plus®, ALLERGAN) will be provided for use at least once a day for 4 weeks. The ocular surface disease index (OSDI), tear film break-up time (TFBUT), Schirmer I test, visual analogue scale (VAS) for self-assessment of ocular discomfort, general assessment (by both acupuncture practitioners and participants) and quality of life (QOL) through the Measure Yourself Medical Outcome Profile-2 (MYMOP-2) will be assessed for approximately 3-months for each study participant. In addition, qualitative study and cost-effectiveness of acupuncture treatment will be conducted.
ClinicalTrials.gov (Identifier: NCT01105221).
既往针刺治疗干眼的研究显示在主观和客观疗效方面均有优势。但是,由于试验质量太低,无法得出确切的结论,因此无法得出明确的结论。因此,本研究旨在避免现有试验的缺陷,并评估针刺治疗干眼的疗效、成本效益和定性特征。
方法/设计:将从三个不同地区的独立医院招募 150 例干眼患者:韩国东医研究院、东国大学 Ilsan 东医院和东新大学光州东医院。根据以往相关研究的数据计算所需的参与者数量。将这些患者随机分为针刺治疗组或人工泪液组。每周 3 次针刺 17 个穴位(双侧 BL2、GB14、TE23、Ex1、ST1、GB20、LI4、LI11 和单 GV23)或每日至少使用 1 次一次性人工泪液(Refresh Plus®,ALLERGAN),持续 4 周。在大约 3 个月的时间内,对每位研究参与者评估眼表疾病指数(OSDI)、泪膜破裂时间(TFBUT)、Schirmer I 试验、眼部不适自我评估的视觉模拟量表(VAS)、一般评估(由针灸医生和参与者共同评估)和生活质量(通过 Measure Yourself Medical Outcome Profile-2(MYMOP-2))。此外,还将进行定性研究和针刺治疗的成本效益分析。
ClinicalTrials.gov(标识符:NCT01105221)。